Home › Compare › ASCCF vs MRK

ASCCF vs MRK: Dividend Comparison 2026

ASCCF yields 0.93% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASCCF wins by $3.52M in total portfolio value· pulled ahead in Year 4
10 years
ASCCF
ASCCF
● Live price
0.93%
Share price
$27.00
Annual div
$0.25
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.55M
Annual income
$2,939,082.90
Full ASCCF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — ASCCF vs MRK

📍 ASCCF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASCCFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASCCF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ASCCF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASCCF
Annual income on $10K today (after 15% tax)
$78.70/yr
After 10yr DRIP, annual income (after tax)
$2,498,220.47/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, ASCCF beats the other by $2,497,412.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASCCF + MRK for your $10,000?

ASCCF: 50%MRK: 50%
100% MRK50/50100% ASCCF
Portfolio after 10yr
$1.79M
Annual income
$1,470,016.60/yr
Blended yield
82.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ASCCF
No analyst data
Altman Z
9.0
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASCCF buys
0
MRK buys
0
No recent congressional trades found for ASCCF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASCCFMRK
Forward yield0.93%3.25% ✓
Annual dividend / share$0.25$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR100% ✓8.2%
Portfolio after 10y$3.55M$30.7K ✓
Annual income after 10y$2,939,082.90 ✓$950.29
Total dividends collected$3.48M$6.1K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ASCCF vs MRK ($10,000, DRIP)

YearASCCF PortfolioASCCF Income/yrMRK PortfolioMRK Income/yrGap
1$10,885$185.19$11,192$351.54$307.00 → MRK
2$12,024$376.78$12,524$392.70$500.00 → MRK
3$13,644$777.94$14,015$438.65$371.00 → MRK
4← crossover$16,249$1,649.95$15,682$489.96+$567.00 → ASCCF
5$21,059$3,672.87$17,547$547.23+$3.5K → ASCCF
6$31,430$8,897.57$19,632$611.16+$11.8K → ASCCF
7$58,453$24,821.89$21,963$682.53+$36.5K → ASCCF
8$148,829$86,284.54$24,571$762.18+$124.3K → ASCCF
9$569,888$410,641.42$27,486$851.08+$542.4K → ASCCF
10$3,548,863$2,939,082.90$30,745$950.29+$3.52M → ASCCF

ASCCF vs MRK: Complete Analysis 2026

ASCCF — Stock

ASICS Corporation manufactures and sells sports goods in Japan, the Americas, Europe, Oceania, Southeast and South Asia, and internationally. It offers sports shoes, apparel, and equipment. The company sells its products under the ASICS, ASICSTIGER, and Onitsuka Tiger brands through 989 retail stores, as well as through online. ASICS Corporation was founded in 1949 and is headquartered in Kobe, Japan.

Full ASCCF Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this ASCCF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASCCF vs SCHDASCCF vs JEPIASCCF vs OASCCF vs KOASCCF vs MAINASCCF vs JNJASCCF vs ABBVASCCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.